Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2017
Reply to F. Liang et al
Jeffrey S Weber, Joel Jiang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2018
Reply to M. Horiguchi et al
Dirk Schadendorf, Joel Jiang, Thomas Kelleher, et al.
Clinical Therapeutics
|
June 17, 2008
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study
Christopher Lucasti, Abel Jasovich, Obiamiwe Umeh, et al.
Plos One
|
March 25, 2022
Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
Nermina Ferizovic, Jessica Summers, Igor Beitia Ortiz de Zárate, et al.
Plos One
|
December 9, 2024
Correction: Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
Nermina Ferizovic, Jessica Summers, Igor Beitia Ortiz de Zárate, et al.
JAMA Oncology
|
July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials
James Larkin, Christopher D Lao, Walter J Urba, et al.
American Heart Journal
|
July 31, 2013
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
JAMA Oncology
|
June 1, 2016
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial
Saby George, Robert J Motzer, Hans J Hammers, et al.
Journal of Comparative Effectiveness Research
|
November 18, 2021
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
Craig M McDonald, Francesco Muntoni, Vinay Penematsa, et al.
Diabetes Care
|
December 4, 2014
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2017
Reply to F. Liang et al
Jeffrey S Weber, Joel Jiang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 17, 2018
Reply to M. Horiguchi et al
Dirk Schadendorf, Joel Jiang, Thomas Kelleher, et al.
Clinical Therapeutics
|
June 17, 2008
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study
Christopher Lucasti, Abel Jasovich, Obiamiwe Umeh, et al.
Plos One
|
March 25, 2022
Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
Nermina Ferizovic, Jessica Summers, Igor Beitia Ortiz de Zárate, et al.
Plos One
|
December 9, 2024
Correction: Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
Nermina Ferizovic, Jessica Summers, Igor Beitia Ortiz de Zárate, et al.
JAMA Oncology
|
July 17, 2015
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials
James Larkin, Christopher D Lao, Walter J Urba, et al.
American Heart Journal
|
July 31, 2013
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
JAMA Oncology
|
June 1, 2016
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial
Saby George, Robert J Motzer, Hans J Hammers, et al.
Journal of Comparative Effectiveness Research
|
November 18, 2021
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
Craig M McDonald, Francesco Muntoni, Vinay Penematsa, et al.
Diabetes Care
|
December 4, 2014
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Page
of 2